Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing

Bio-Rad Laboratories (BIO) shares rose 19.1% in the past month, driven by digital PCR demand and steady Clinical Diagnostics performance. However, Life Science demand remains weak, and the stock trades at a premium valuation. Management expects cost savings to support margins, but investors must weigh execution against subdued end markets. BIO's Digital PCR revenues grew 6% YoY, with instrument revenues up over 20%. Clinical Diagnostics sales were $399M, up 2.6% YoY. Life Science sales fell 4.1%

South Korean biotech stocks rose as the KOSDAQ rebounded. FromBio surged to the daily upper limit after trading resumed following a 5-for-1 reverse stock split, closing at 3,330 won (+29.82%). It reported 72.2b won revenue in 2025 and an 18.6b won operating loss. Curacle jumped over 18% on hopes of follow-on licensing after its $1.08b MT-103 deal.

Bio-Rad Laboratories’ Q2 2026 earnings call cited 10% sequential revenue growth, with year-over-year pressure from softer academic research and cautious biopharma demand. Management reaffirmed full-year currency-neutral revenue guidance of -3% to +0.5% and expects ddPCR instrument revenue up 20% and $30m to $35m net annual savings by 2027.

Bio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.

BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.